Outcome
    Moderate Evidence
    Effectiveness 3/5

    Saccharomyces Boulardii for Fungal Infection Resistance

    S. boulardii is itself a yeast, and it competes with Candida in the gut, with reasonable evidence for reducing colonisation.

    Overview

    S. boulardii is itself a yeast, and it competes with Candida in the gut, with reasonable evidence for reducing colonisation.

    Verdict

    Mixed evidence

    Better evidence than most antifungal botanicals, particularly around antibiotic use.

    How It Works

    S. boulardii inhibits Candida adhesion to intestinal epithelium, secretes capric acid that suppresses hyphal formation, and reduces the inflammatory response to Candida colonisation.

    Dosing & Protocol

    Typical dose

    Recommended dose
    250-500 mg (5-10 billion CFU) once or twice daily
    Expected timeframe
    4-8 weeks

    Protocol

    form
    Saccharomyces boulardii CNCM I-745; a yeast, so unaffected by antibacterial antibiotics but inactivated by antifungal drugs
    duration
    2-4 weeks
    co factor
    Evidence is mixed. In vitro and animal work is reasonably consistent: S. boulardii inhibits Candida albicans adhesion to intestinal epithelium, suppresses hyphal transition and biofilm formation, and reduces Candida translocation in animal models, with capric acid among the proposed active components. Human data are limited to reduced Candida colonisation in specific clinical populations such as preterm infants and critically ill patients - and the latter group is one in which S. boulardii itself is contraindicated. No trial has shown reduced fungal infection incidence in healthy adults, and colonisation is not infection.
    titration
    Up to 500 mg twice daily; 1,000 mg/day is the usual upper dose in trials
    starting dose
    250 mg twice daily if used, with or without food

    Evidence

    What the studies say

    Randomised trials support S. boulardii for antibiotic-associated diarrhoea, with several showing reduced intestinal Candida colonisation. Evidence for preventing clinical fungal infection in immunocompetent adults is thinner.

    Probiotics for vulvovaginal candidiasis in non-pregnant women

    Score: 8/10
    2017
    systematic_review
    n=1656

    Xie HY, Feng D, Wei DM

    Probiotic adjuncts, including yeast and lactobacillus preparations, showed low-certainty benefit in candidiasis.

    View source

    Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants

    Score: 6/10
    2013
    rct
    n=181

    Saccharomyces boulardii was compared with nystatin for prevention of fungal colonization and invasive fungal infection in premature infants.

    View source

    Safety

    Caveats

    Should not be used in immunocompromised patients or those with central venous catheters, where fungaemia has been reported.

    Less likely to help if

    People whose recurrent infections are driven by uncontrolled diabetes.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.